Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study

References

• Kerkhof M, Tran TN, Soriano JB, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2018;73(2):116–124. doi:10.1136/thoraxjnl-2017-210531
   PubMed Web of Science ®Google Scholar
• Khan A, Gouia I, Kamat S, et al. Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis. Eur Respir J. 2020;56:232. doi:10.1183/13993003.congress-2020.232
   Web of Science ®Google Scholar
• Novelli F, Bacci E, Latorre M, et al. Comorbidities are associated with different features of severe asthma. Clin Mol Allergy. 2018;16:25. doi:10.1186/s12948-018-0103-x
   PubMedGoogle Scholar
• Bilodeau L, Boulay ME, Prince P, Boisvert P, Boulet LP. Comparative clinical and airway inflammatory features of asthmatics with or without polyps. Rhinology. 2010;48(4):420–425. doi:10.4193/Rhino09.095
   PubMed Web of Science ®Google Scholar
• Tay TR, Radhakrishna N, Hore-Lacy F, et al. Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology. 2016;21(8):1384–1390. doi:10.1111/resp.12838
   PubMed Web of Science ®Google Scholar
• Tay TR, Hew M. Comorbid “treatable traits” in difficult asthma: current evidence and clinical evaluation. Allergy. 2018;73(7):1369–1382. doi:10.1111/all.13370
   PubMed Web of Science ®Google Scholar
• Alobid I, Benítez P, Bernal-Sprekelsen M, et al. Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments. Allergy. 2005;60(4):452–458. doi:10.1111/j.1398-9995.2005.00725.x
   PubMed Web of Science ®Google Scholar
• Huang CC, Chang PH, Wu PW, et al. Impact of nasal symptoms on the evaluation of asthma control. Medicine. 2017;96(8):e6147. doi:10.1097/MD.0000000000006147
   PubMed Web of Science ®Google Scholar
• Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014;111(14):5153–5158. doi:10.1073/pnas.1324022111
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa1804092
   PubMed Web of Science ®Google Scholar
• Maspero JF, Katelaris CH, Busse WW, et al. Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2020;8(2):527–539.e9. doi:10.1016/j.jaip.2019.07.016
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Denicolò CF, Rossini L, Marseglia A, Marseglia GL. The nose and the lung: united airway disease? Front Pediatr. 2017;5:44. doi:10.3389/fped.2017.00044
   PubMed Web of Science ®Google Scholar
• Hamada K, Oishi K, Chikumoto A, et al. Impact of sinus surgery on type 2 airway and systemic inflammation in asthma. J Asthma. 2021;58(6):750–758. doi:10.1080/02770903.2020.1729380
   PubMed Web of Science ®Google Scholar
• Khan A, Reaney M, Guillemin I, et al. Development of Sinonasal Outcome Test (SNOT-22) domains in chronic rhinosinusitis with nasal polyps. Laryngoscope. 2021. doi:10.1002/lary.29766
   Web of Science ®Google Scholar
• Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item sinonasal outcome test. Clin Otolaryngol. 2009;34(5):447–454. doi:10.1111/j.1749-4486.2009.01995.x
   PubMed Web of Science ®Google Scholar
• Janssen MF, Szende A, Cabases J, Ramos-Goñi JM, Vilagut G, König HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20(2):205–216. doi:10.1007/s10198-018-0955-5
   PubMed Web of Science ®Google Scholar
• Phillips KM, Talat R, Caradonna DS, Gray ST, Sedaghat AR. Quality of life impairment due to chronic rhinosinusitis in asthmatics is mediated by asthma control. Rhinology. 2019;57(6):430–435. doi:10.4193/Rhin19.207
   PubMed Web of Science ®Google Scholar
• Remenschneider AK, D’Amico L, Gray ST, Holbrook EH, Gliklich RE, Metson R. The EQ-5D: a new tool for studying clinical outcomes in chronic rhinosinusitis. Laryngoscope. 2015;125(1):7–15. doi:10.1002/lary.24715
   PubMed Web of Science ®Google Scholar
• Kim Do H, Han K, Kim SW. Effect of chronic rhinosinusitis with or without nasal polyp on quality of life in South Korea: 5th Korea National Health and nutrition examination survey Korean. Clin Exp Otorhinolaryngol. 2016;9(2):150–156. doi:10.21053/ceo.2015.01053
   PubMed Web of Science ®Google Scholar
• Bachert C, Hellings PW, Mullol J, et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy. 2020;75(1):148–157. doi:10.1111/all.13984
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9(3):1133–1141. doi:10.1016/j.jaip.2020.09.063
   PubMed Web of Science ®Google Scholar
• Lee SE, Hopkins C, Mullol J, et al. Dupilumab improves health related quality of life: results from the phase 3 SINUS studies. Allergy. 2022. doi:10.1111/all.15222
   Web of Science ®Google Scholar
• Bachert C, Bhattacharyya N, Desrosiers M, Khan AH. Burden of disease in chronic rhinosinusitis with nasal polyps. J Asthma Allergy. 2021;14:127–134. doi:10.2147/JAA.S290424
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Bachert C, Amin N, et al. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma. Ann Allergy Asthma Immunol. 2021;126(5):584–592.e1. doi:10.1016/j.anai.2021.01.012
   PubMed Web of Science ®Google Scholar